Alphabet’s Isomorphic Labs, the AI‑driven biolab led by Nobel laureate Demis Hassabis, is reportedly negotiating a new funding round that would value the company at $40 billion. The fresh capital is meant to speed up its drug‑development programs. Other AI firms such as China’s DeepSeek, Moonshot and OpenAI are also chasing large investments, showing high market interest in AI despite warnings of a possible bubble.
Why it matters
If the financing closes, Isomorphic Labs could bring AI‑designed medicines to market faster, affecting patients and pharma partners.
